ES2146649T3 - Compuestos de polioximas y su preparacion. - Google Patents

Compuestos de polioximas y su preparacion.

Info

Publication number
ES2146649T3
ES2146649T3 ES94913192T ES94913192T ES2146649T3 ES 2146649 T3 ES2146649 T3 ES 2146649T3 ES 94913192 T ES94913192 T ES 94913192T ES 94913192 T ES94913192 T ES 94913192T ES 2146649 T3 ES2146649 T3 ES 2146649T3
Authority
ES
Spain
Prior art keywords
compounds
ortogonal
oxin
new
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913192T
Other languages
English (en)
Inventor
Keith Rose
Robin Ewart Offord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/105,904 external-priority patent/US6001364A/en
Priority claimed from US08/114,877 external-priority patent/US6174530B1/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2146649T3 publication Critical patent/ES2146649T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTA INVENCION PROPORCIONA UNOS COMPUESTOS DE MATERIA DEFINIDA ESENCIALMENTE HOMOGENEA Y HETERO-POLIOXINAS DE UNA ESTRUCTURA DEFINIDA QUE CONTIENEN UNA ESTRUCTURA DE PLACA DE ASIENTO CON UNA PLURALIDAD DE ENLACES DE OXINA, DONDE CADA ENLACE DE OXINA UNE UNA MOLECULA ACTIVA ESPECIFICA A LA PLACA DE ASIENTO. TAMBIEN SE PROPORCIONAN NUEVAS PLACAS DE ASIENTO QUE TIENEN UNA PLURALIDAD DE GRUPOS REACTIVOS COMPLEMENTARIOS FORMADORES DE OXINA Y NUEVAS MOLECULAS ESPECIFICAMENTE REACTIVAS QUE TIENEN UN GRUPOS REACTIVOS COMPLEMENTARIOS FORMADORES DE OXINA. ESTA INVENCION TAMBIEN PROPORCIONA METODOS PARA PREPARAR ESTOS NUEVOS COMPUESTOS DE MATERIA, LIGANDO DE FORMA QUIMIOSELECTIVA, MEDIANTE LA FORMACION DE ENLACES DE OXINA, UN GRUPO REACTIVO ORTOGONAL COMPLEMENTARIO DE LA PLACA DE ASIENTO A UN GRUPO ORTOGONAL REACTIVO COMPLEMENTARIO DE UNA MOLECULA ACTIVA ESPECIFICA. LA INVENCION TAMBIEN DESCRIBE LOS METODOS PARA UTILIZAR ESTOS COMPUESTOS DEFINIDOS DE MATERIA ASI COMO LOS COMPUESTOS FARMACEUTICOS QUE CONTIENEN ESTOS COMPUESTOS DE MATERIA DEFINIDA Y LOS METODOS PARA SU USO.
ES94913192T 1993-05-05 1994-05-05 Compuestos de polioximas y su preparacion. Expired - Lifetime ES2146649T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5759493A 1993-05-05 1993-05-05
US08/105,904 US6001364A (en) 1993-05-05 1993-08-31 Hetero-polyoxime compounds and their preparation by parallel assembly
US08/114,877 US6174530B1 (en) 1993-05-05 1993-08-31 Homogeneous polyoxime compositions and their preparation by parallel assembly

Publications (1)

Publication Number Publication Date
ES2146649T3 true ES2146649T3 (es) 2000-08-16

Family

ID=27369284

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913192T Expired - Lifetime ES2146649T3 (es) 1993-05-05 1994-05-05 Compuestos de polioximas y su preparacion.

Country Status (11)

Country Link
US (1) US6663869B1 (es)
EP (1) EP0697891B1 (es)
JP (1) JP3734828B2 (es)
AT (1) ATE191148T1 (es)
AU (1) AU686153B2 (es)
CA (1) CA2162157A1 (es)
DE (1) DE69423753T2 (es)
DK (1) DK0697891T3 (es)
ES (1) ES2146649T3 (es)
GR (1) GR3033699T3 (es)
PT (1) PT697891E (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
BRPI0409976A (pt) * 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
US8795680B2 (en) * 2006-07-21 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid
WO2008087186A2 (en) * 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20100016238A1 (en) * 2007-01-18 2010-01-21 Novo Nordisk A/S Peptides for Use in the Treatment of Obesity
US20100022446A1 (en) * 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
JP2012509862A (ja) * 2008-11-25 2012-04-26 ノヴォ・ノルディスク・アー／エス 肥満の治療のためのペプチド
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
JP6564539B1 (ja) * 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4865835A (en) 1982-06-02 1989-09-12 Begent Richard H J Diagnosis and treatment of tumors
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
JPS59215321A (ja) 1983-05-23 1984-12-05 Sumitomo Chem Co Ltd 二官能性配位子化合物を結合した反応性高分子
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4652440A (en) 1984-05-03 1987-03-24 Paik Chang H Method of stably radiolabeling antibodies with technetium and rhenium
IL71947A (en) 1984-05-29 1987-10-30 Yeda Research And Dev Comp Ltd Enzyme hydrazides and method for detection and determination of glycoconjugates
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
JPH0611290B2 (ja) 1986-11-05 1994-02-16 住友ベークライト株式会社 ポリビニルアルコ−ルゲルのγ線滅菌法
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5084266A (en) 1988-02-03 1992-01-28 The University Of Melbourne Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
US4857599A (en) 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
GB8820377D0 (en) 1988-08-26 1988-09-28 Offord R E Chemical compounds
GB9004538D0 (en) * 1990-02-28 1990-04-25 Offord Robin E Chemical compounds
US5011676A (en) 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
DE69126124T2 (de) * 1990-09-28 1997-08-28 Neorx Corp Polymere träger zur freisetzung kovalent gebundener wirkstoffe
GB9102450D0 (en) 1991-02-05 1991-03-20 Sandoz Ltd Improvements in or relating to organic compounds
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
US6174530B1 (en) * 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
US6001364A (en) * 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly

Also Published As

Publication number Publication date
JPH08510210A (ja) 1996-10-29
AU6543894A (en) 1994-11-21
EP0697891B1 (en) 2000-03-29
EP0697891A1 (en) 1996-02-28
GR3033699T3 (en) 2000-10-31
AU686153B2 (en) 1998-02-05
CA2162157A1 (en) 1994-11-10
ATE191148T1 (de) 2000-04-15
JP3734828B2 (ja) 2006-01-11
PT697891E (pt) 2000-09-29
DK0697891T3 (da) 2000-09-04
US6663869B1 (en) 2003-12-16
DE69423753T2 (de) 2000-11-02
DE69423753D1 (de) 2000-05-04

Similar Documents

Publication Publication Date Title
ES2146649T3 (es) Compuestos de polioximas y su preparacion.
ES2115298T3 (es) Nuevos derivados de 1-fenil-3-dimetil-amino-propano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE224360T1 (de) Adamantan-derivate
PT1036058E (pt) Deribvados de adamantano
MX9701497A (es) Polimeros de ioneno que contienen aniones biologicamente activos.
AR000169A1 (es) Tramo de vía para un sistema transportador y el sistema transportador que lo comprende
BR0208443A (pt) Kits de multicomponentes e combinações, sua aplicação e argamassas sintéticas obtenìveis
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
HRP20130413A2 (hr) Taci-imunoglobulin fuzijski proteini
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
DE69804134D1 (de) Mit metallfasern bewehrter beton, zementmatrix und vormischung zum herstellen der matrix und dem beton
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
EP0904100A4 (en) RECIPE LIGAND EASIER THE GIVING OF BIOLOGICALLY ACTIVE MOLECULES
ES2193144T3 (es) Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
ES2119999T5 (es) Adsorbentes quirales y preparacion de los mismos asi como compuestos en los que se basan los adsorbentes y preparacion de estos compuestos.
AR019631A1 (es) Agentes terapeuticos nuevos que modulan receptores de 5-ht.
BRPI0508227A (pt) géis poliméricos interligados e uso de tais géis poliméricos na recuperação de hidrocarboneto
ES2100051T3 (es) Sintesis de bloques dimeros y su uso en el ensamblaje de oligonucleotidos.
ES2162473T3 (es) Procedimiento para preparar fosfinas ciclicas.
ES2095987T3 (es) Sistema terapeutico transdermal para la administracion de farmacos que tienen actividad broncodilatadora.
TR200302178T4 (tr) Ağrı ve alerjik reaksiyonlarla mücadele için sübstitüe edilmiş pirrol mannich bazları.
ATE233290T1 (de) Mittels kovalent verknüpfter netzwerke vernetzte, disperse zwei- oder mehr-phasensysteme
AR009322A1 (es) Nuevas aril-piridazinas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 697891

Country of ref document: ES